First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated
Trial to enrol approximately 2,250 adults to assess safety and immunogenicity of AZD2816 against the SARS-CoV-2 virusThe first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 were vaccinated today to assess its safety and immunogenicity in both previously vaccinated and unvaccinated adults. The trial will recruit approximately 2,250 participants across UK, South Africa, Brazil and Poland. AZD2816 will be administered to individuals who have previously been fully vaccinated with two doses of Vaxzevria or an mRNA vaccine, at least three months after